Valeant's mistakes raised profit, destroyed value: Ackman
Pharma company raised drug prices sky-high after strategic acquisitions
Washington
AFTER US$77 billion in lost market value, congressional hearings and corporate stumbles, Valeant Pharmaceuticals International Inc's CEO and its biggest hedge fund booster stood before a Senate committee, raised their right hands in truth, and said the drug company had gotten things wrong.
"We have made mistakes," Mike Pearson, Valeant's CEO, said at the Special Committee on Aging's hearing on high drug prices. "Valeant was too aggressive. And I, as a leader, was too aggressive."
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cordlife served letter of demand, notice of claim from customers
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead independent director
GSK profit drops 23% in Q1 on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability